Literature DB >> 20543859

The ubiquitous nature of cancer: the role of the SCF(Fbw7) complex in development and transformation.

K M Crusio1, B King, L B Reavie, I Aifantis.   

Abstract

The ubiquitin-proteasome system (UPS) is a multi-subunit pathway that allows for ubiquitin modification of proteins and leads to either degradation or other non-proteolytic processes such as trafficking or transcriptional activation. Given its role as a regulator of cellular homeostasis it is not surprising that members of the UPS are frequently aberrantly expressed in a number of disease states including cancer. This review will focus on one member of the UPS, the F-box protein, Fbw7 (also known as Sel-10, Ago, hCDC4) and mechanisms by which Fbw7 interacts with its substrates in the context of development and tumorigenesis will be discussed. In addition, antagonists of this pathway as well as current and future therapeutics for the UPS will be examined.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20543859      PMCID： PMC3651593          DOI： 10.1038/onc.2010.222

Source DB:  PubMed          Journal:  Oncogene        ISSN： 0950-9232            Impact factor:   9.867


  80 in total

1.  Transcriptional regulatory networks downstream of TAL1/SCL in T-cell acute lymphoblastic leukemia.

Authors:  Teresa Palomero; Duncan T Odom; Jennifer O'Neil; Adolfo A Ferrando; Adam Margolin; Donna S Neuberg; Stuart S Winter; Richard S Larson; Wei Li; X Shirley Liu; Richard A Young; A Thomas Look
Journal:  Blood       Date:  2006-04-18       Impact factor: 22.113

2.  Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7.

Authors:  Masayoshi Yada; Shigetsugu Hatakeyama; Takumi Kamura; Masaaki Nishiyama; Ryosuke Tsunematsu; Hiroyuki Imaki; Noriko Ishida; Fumihiko Okumura; Keiko Nakayama; Keiichi I Nakayama
Journal:  EMBO J       Date:  2004-04-22       Impact factor: 11.598

3.  The Notch intracellular domain is ubiquitinated and negatively regulated by the mammalian Sel-10 homolog.

Authors:  C Oberg; J Li; A Pauley; E Wolf; M Gurney; U Lendahl
Journal:  J Biol Chem       Date:  2001-07-18       Impact factor: 5.157

4.  Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbw7).

Authors:  Anders Sundqvist; Maria T Bengoechea-Alonso; Xin Ye; Vasyl Lukiyanchuk; Jianping Jin; J Wade Harper; Johan Ericsson
Journal:  Cell Metab       Date:  2005-06       Impact factor: 27.287

5.  Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene.

Authors:  Jian-Hua Mao; Jesus Perez-Losada; Di Wu; Reyno Delrosario; Ryosuke Tsunematsu; Keiichi I Nakayama; Ken Brown; Sheila Bryson; Allan Balmain
Journal:  Nature       Date:  2004-12-09       Impact factor: 49.962

6.  SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box.

Authors:  C Bai; P Sen; K Hofmann; L Ma; M Goebl; J W Harper; S J Elledge
Journal:  Cell       Date:  1996-07-26       Impact factor: 41.582

Review 7.  Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy.

Authors:  Robert C Kane; Peter F Bross; Ann T Farrell; Richard Pazdur
Journal:  Oncologist       Date:  2003

8.  An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.

Authors:  Teresa A Soucy; Peter G Smith; Michael A Milhollen; Allison J Berger; James M Gavin; Sharmila Adhikari; James E Brownell; Kristine E Burke; David P Cardin; Stephen Critchley; Courtney A Cullis; Amanda Doucette; James J Garnsey; Jeffrey L Gaulin; Rachel E Gershman; Anna R Lublinsky; Alice McDonald; Hirotake Mizutani; Usha Narayanan; Edward J Olhava; Stephane Peluso; Mansoureh Rezaei; Michael D Sintchak; Tina Talreja; Michael P Thomas; Tary Traore; Stepan Vyskocil; Gabriel S Weatherhead; Jie Yu; Julie Zhang; Lawrence R Dick; Christopher F Claiborne; Mark Rolfe; Joseph B Bolen; Steven P Langston
Journal:  Nature       Date:  2009-04-09       Impact factor: 49.962

9.  Mastermind recruits CycC:CDK8 to phosphorylate the Notch ICD and coordinate activation with turnover.

Authors:  Christy J Fryer; J Brandon White; Katherine A Jones
Journal:  Mol Cell       Date:  2004-11-19       Impact factor: 17.970

Review 10.  The ubiquitin system, disease, and drug discovery.

Authors:  Matthew D Petroski
Journal:  BMC Biochem       Date:  2008-10-21       Impact factor: 4.059
View more
  66 in total

Review 1.  SCF ubiquitin ligase-targeted therapies.

Authors:  Jeffrey R Skaar; Julia K Pagan; Michele Pagano
Journal:  Nat Rev Drug Discov       Date:  2014-11-14       Impact factor: 84.694

2.  Negative regulation of HIF-1α by an FBW7-mediated degradation pathway during hypoxia.

Authors:  Jessica M Cassavaugh; Sarah A Hale; Theresa L Wellman; Alan K Howe; Cheung Wong; Karen M Lounsbury
Journal:  J Cell Biochem       Date:  2011-12       Impact factor: 4.429

3.  The Fbw7 tumor suppressor regulates nuclear factor E2-related factor 1 transcription factor turnover through proteasome-mediated proteolysis.

Authors:  Madhurima Biswas; Diane Phan; Momoko Watanabe; Jefferson Y Chan
Journal:  J Biol Chem       Date:  2011-09-27       Impact factor: 5.157

4.  The tumour suppressor C/EBPδ inhibits FBXW7 expression and promotes mammary tumour metastasis.

Authors:  Kuppusamy Balamurugan; Ju-Ming Wang; Hsin-Hwa Tsai; Shikha Sharan; Miriam Anver; Robert Leighty; Esta Sterneck
Journal:  EMBO J       Date:  2010-11-12       Impact factor: 11.598

Review 5.  Dysregulation of ubiquitin ligases in cancer.

Authors:  Jianfei Qi; Ze'ev A Ronai
Journal:  Drug Resist Updat       Date:  2015-09-28       Impact factor: 18.500

Review 6.  The two faces of FBW7 in cancer drug resistance.

Authors:  Zhiwei Wang; Hidefumi Fukushima; Daming Gao; Hiroyuki Inuzuka; Lixin Wan; Alan W Lau; Pengda Liu; Wenyi Wei
Journal:  Bioessays       Date:  2011-08-30       Impact factor: 4.345

7.  Downregulation of specific FBXW7 isoforms with differential effects in T-cell lymphoblastic lymphoma.

Authors:  Irene Vázquez-Domínguez; Laura González-Sánchez; Pilar López-Nieva; Pablo Fernández-Navarro; María Villa-Morales; María Á Cobos-Fernández; Isabel Sastre; Mario F Fraga; Agustín F Fernández; Marcos Malumbres; María Salazar-Roa; Osvaldo Graña-Castro; Javier Santos; Pilar Llamas; José L López-Lorenzo; José Fernández-Piqueras
Journal:  Oncogene       Date:  2019-02-11       Impact factor: 9.867

Review 8.  The role of aberrant proteolysis in lymphomagenesis.

Authors:  Anagh A Sahasrabuddhe; Kojo S J Elenitoba-Johnson
Journal:  Curr Opin Hematol       Date:  2015-07       Impact factor: 3.284

9.  Cell cycle-dependent degradation of the methyltransferase SETD3 attenuates cell proliferation and liver tumorigenesis.

Authors:  Xiaoqing Cheng; Yuan Hao; Wenjie Shu; Mengjie Zhao; Chen Zhao; Yuan Wu; Xiaodan Peng; Pinfang Yao; Daibiao Xiao; Guoliang Qing; Zhengying Pan; Lei Yin; Desheng Hu; Hai-Ning Du
Journal:  J Biol Chem       Date:  2017-04-25       Impact factor: 5.157

Review 10.  Roles of F-box proteins in cancer.

Authors:  Zhiwei Wang; Pengda Liu; Hiroyuki Inuzuka; Wenyi Wei
Journal:  Nat Rev Cancer       Date:  2014-04       Impact factor: 60.716
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.